CASE REPORT
Moxifloxacin Concentration and Proteomic Analysis of Aqueous Humor in Human Uveitis Associated with Oral Moxifloxacin Therapy
David M Hinkle1, *, Nicole A Kruh-Garcia2, Jonathan N Kruh3, Carolyn Broccardo4, Priyanka Doctor5, C Stephen Foster5, 6, 7
Article Information
Identifiers and Pagination:
Year: 2017Volume: 11
First Page: 107
Last Page: 116
Publisher ID: TOOPHTJ-11-107
DOI: 10.2174/1874364101711010107
Article History:
Received Date: 30/06/2016Revision Received Date: 08/12/2016
Acceptance Date: 02/04/2017
Electronic publication date: 12/06/2017
Collection year: 2017

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Purpose:
The aim was to report the aqueous humor moxifloxacin concentration and proteome profile of an individual with bilateral uveitis-like syndrome with pigment dispersion.
Methods:
Multiple reactions monitoring mass spectrometry quantified the aqueous concentration of moxifloxacin in the affected individual. Shotgun proteomic analysis performed via liquid chromatography tandem mass spectrometry (LC-MS/MS) defined the protein profile in the affected individual and unaffected control samples.
Results:
Moxifloxacin was present at higher than expected levels in aqueous humor 18 days following oral administration. One-third of the proteins were identified by significantly lower spectral counts in the aqueous of the individual with moxifloxacin associated uveitis compared to the unaffected control.
Conclusion:
Moxifloxacin was detected in aqueous humor 18 days following the completion of oral administration. These results suggest that moxifloxacin toxicity may be responsible for the uveitis-like syndrome with pigment dispersion syndrome induced by moxifloxacin therapy.